Balentine LLC’s Jazz Pharmaceuticals JAZZ Stock Holding History

Balentine LLC’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,471	Closed	-$234K	–	646
2022 Q4	$234K	Sell	1,471 -427	-22%	-$62.6K	0.01%	496
2022 Q3	$253K	Buy	1,898 +224	+13%	+$34.1K	0.01%	430
2022 Q2	$261K	Buy	1,674 +14	+0.8%	+$2.15K	0.01%	467
2022 Q1	$258K	Buy	+1,660	New	+$241K	0.01%	475
2020 Q3	–	Sell	-512	Closed	-$56K	–	517
2020 Q2	$56K	Buy	512 +5	+1%	+$553	﹤0.01%	230
2020 Q1	$51K	Hold	507	–	–	﹤0.01%	178
2019 Q4	$76K	Buy	+507	New	+$69K	﹤0.01%	145
2019 Q3	–	Sell	-9	Closed	-$1K	–	778
2019 Q2	$1K	Buy	+9	New	+$1.21K	﹤0.01%	706
2018 Q1	–	Sell	-507	Closed	-$68K	–	295
2017 Q4	$68K	Hold	507	–	–	0.01%	241
2017 Q3	$74K	Hold	507	–	–	0.01%	216
2017 Q2	$79K	Hold	507	–	–	0.01%	194
2017 Q1	$74K	Buy	+507	New	+$66K	0.01%	190

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Balentine LLC's JAZZ Position: Q1 2023 in Review

Balentine LLC sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 1,471 shares — an estimated $234K sold.

Balentine LLC first reported a position in JAZZ in Q1 2017 and held it in 12 quarters. The position peaked at $261K in Q2 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Balentine LLC reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Balentine LLC sold 1,471 Jazz Pharmaceuticals shares in Q1 2023, an estimated $234K.
Balentine LLC first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Balentine LLC's Jazz Pharmaceuticals position peaked at $261K in Q2 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Balentine LLC's 13F filing for Q1 2023, filed 11 May 2023.